The MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) play an important role in cancer development as well as in innate and acquired resistance to lung cancer treatment, including EGFR inhibition [43]. Here, MET is linked to lung carcinoma.